Skip to content
Resources > Reports

The Ultimate Guide for Conducting Efficient and Comprehensive Due Diligence

Fluctuating interest rates and tightened credit have contributed to slowed M&A deal activity throughout 2023. Lingering macroeconomic uncertainty is requiring investors to be more critical than ever in their analyses in order to make informed decisions.

Over the past year, activity on the AlphaSense platform has increased by >50% for documents referencing ‘due diligence.’ As the data indicates—conducting the right due diligence is critical to deal success.

In this whitepaper, we examine the latest trends and best practices to help you navigate the shifting M&A landscape. Download the guide to uncover:

  • The current state of the market and economic factors that are influencing M&A deal activity
  • The right types of questions to ask a prospective seller that company documents and correspondence may not overtly address
  • An essential due diligence checklist covering potential areas of concern and vital documents needed to get the full picture

Explore more

APAC Macro Briefing 2026: Risk Meets Opportunity

In this report, we show how resources and workflows available in the AlphaSense platform can help contextualize the APAC macro environment, exploring the key implications for corporate leaders and investors across sectors.
Title slide for "APAC Macro Briefing 2026: Risk Meets Opportunity" with a map of the Asia-Pacific region.

Top AI Use Cases for Private Equity

In this report, discover how private equity teams are leveraging AI to accelerate conviction with speed. With purpose built, AI-driven solutions like AlphaSense, teams are gaining a competitive advantage with custom workflows and unmatched content sets for the most differentiated deal intelligence.
Top AI Use Cases For Private Equity by Barb Tague, Financial Research Leader. Illustration featuring isometric buildings and currency symbols.

AI in Drug Development 2026: From Experimentation to Execution

Learn how AI is reshaping drug development in real time, turning AI execution into a key competitive differentiator.
Presentation slide titled "AI in Drug Development 2026: From Experimentation to Execution" by Sara Mallatt and Sean Carmichael, with line art of laboratory equipment.

Transform intelligence
into advantage

Develop bold strategies, seize opportunities,
and lead with clarity and confidence.